Literature DB >> 18784617

Multidrug resistance in epilepsy and polymorphisms in the voltage-gated sodium channel genes SCN1A, SCN2A, and SCN3A: correlation among phenotype, genotype, and mRNA expression.

Patrick Kwan1, Wai Sang Poon, Ho-Keung Ng, David E Kang, Virginia Wong, Ping Wing Ng, Colin H T Lui, Ngai Chuen Sin, Ka S Wong, Larry Baum.   

Abstract

OBJECTIVES: Many antiepileptic drugs (AEDs) prevent seizures by blocking voltage-gated brain sodium channels. However, treatment is ineffective in 30% of epilepsy patients, which might, at least in part, result from polymorphisms of the sodium channel genes. We investigated the association of AED responsiveness with genetic polymorphisms and correlated any association with mRNA expression of the neuronal sodium channels.
METHODS: We performed genotyping of tagging and candidate single nucleotide polymorphisms (SNPs) of SCN1A, 2A, and 3A in 471 Chinese epilepsy patients (272 drug responsive and 199 drug resistant). A total of 27 SNPs were selected based on the HapMap database. Genotype distributions in drug-responsive and drug-resistant patients were compared. SCN2A mRNA was quantified by real-time PCR in 24 brain and 57 blood samples. Its level was compared between patients with different genotypes of an SCN2A SNP found to be associated with drug responsiveness.
RESULTS: SCN2A IVS7-32A>G (rs2304016) A alleles were associated with drug resistance (odds ratio = 2.1, 95% confidence interval: 1.2-3.7, P=0.007). Haplotypes containing the IVS7-32A>G allele A were also associated with drug resistance. IVS7-32A>G is located within the putative splicing branch site for splicing exons 7 and 9. PCR of reverse-transcribed RNA from blood or brain of patients with different IVS7-32A>G genotypes using primers in exons 7 and 9 showed no skipping of exon 8, and real-time PCR showed no difference in SCN2A mRNA levels among genotypes.
CONCLUSION: Results of this study suggest an association between SCN2A IVS7-32A>G and AED responsiveness, without evidence of an effect on splicing or mRNA expression.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18784617     DOI: 10.1097/FPC.0b013e3283117d67

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN: 1744-6872            Impact factor:   2.089


  28 in total

1.  Biomarkers for antiepileptic drug response.

Authors:  Tracy A Glauser
Journal:  Biomark Med       Date:  2011-10       Impact factor: 2.851

2.  Case-control association study of polymorphisms in the voltage-gated sodium channel genes SCN1A, SCN2A, SCN3A, SCN1B, and SCN2B and epilepsy.

Authors:  Larry Baum; Batoul Sadat Haerian; Ho-Keung Ng; Virginia C N Wong; Ping Wing Ng; Colin H T Lui; Ngai Chuen Sin; Chunbo Zhang; Brian Tomlinson; Gary Wing-Kin Wong; Hui Jan Tan; Azman Ali Raymond; Zahurin Mohamed; Patrick Kwan
Journal:  Hum Genet       Date:  2013-12-13       Impact factor: 4.132

3.  Differential role of sodium channels SCN1A and SCN2A gene polymorphisms with epilepsy and multiple drug resistance in the north Indian population.

Authors:  Ram Lakhan; Ritu Kumari; Usha K Misra; Jayanti Kalita; Sunil Pradhan; Balraj Mittal
Journal:  Br J Clin Pharmacol       Date:  2009-08       Impact factor: 4.335

4.  PharmGKB summary: carbamazepine pathway.

Authors:  Caroline F Thorn; Susan G Leckband; John Kelsoe; J Steven Leeder; Daniel J Müller; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2011-12       Impact factor: 2.089

5.  Evaluating the Role of Genetic Variants on first-line antiepileptic drug response in North India: Significance of SCN1A and GABRA1 Gene Variants in Phenytoin Monotherapy and its Serum Drug Levels.

Authors:  Ruchi Baghel; Sandeep Grover; Harpreet Kaur; Ajay Jajodia; Chitra Rawat; Ankit Srivastava; Suman Kushwaha; Rachna Agarwal; Sangeeta Sharma; Ritushree Kukreti
Journal:  CNS Neurosci Ther       Date:  2016-06-01       Impact factor: 5.243

Review 6.  Distribution and function of voltage-gated sodium channels in the nervous system.

Authors:  Jun Wang; Shao-Wu Ou; Yun-Jie Wang
Journal:  Channels (Austin)       Date:  2017-11-08       Impact factor: 2.581

7.  Association between two SCN1A polymorphisms and resistance to sodium channel blocking AEDs: a meta-analysis.

Authors:  Yi Bao; Xinzhu Liu; Zheng Xiao
Journal:  Neurol Sci       Date:  2018-03-26       Impact factor: 3.307

8.  SCN1A and SCN2A polymorphisms are associated with response to valproic acid in Chinese epilepsy patients.

Authors:  Lihong Shi; Miaomiao Zhu; Huilan Li; Zhipeng Wen; Xiaoping Chen; Jia Luo; Cong Lin; Zanling Zhang
Journal:  Eur J Clin Pharmacol       Date:  2019-01-28       Impact factor: 2.953

9.  Exploring the genomic basis of pharmacoresistance in epilepsy: an integrative analysis of large-scale gene expression profiling studies on brain tissue from epilepsy surgery.

Authors:  Nasir Mirza; Olga Vasieva; Anthony Guy Marson; Munir Pirmohamed
Journal:  Hum Mol Genet       Date:  2011-08-18       Impact factor: 6.150

10.  Rapid loss of efficacy to the antiseizure drugs lamotrigine and carbamazepine: a novel experimental model of pharmacoresistant epilepsy.

Authors:  Ajay K Srivastava; Anitha B Alex; Karen S Wilcox; H Steve White
Journal:  Epilepsia       Date:  2013-06-10       Impact factor: 5.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.